TEVJF (TEVJF)

2026-07-31. The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with their 2026 Q2 earnings call.

TEVA misses Q2 earnings estimates as Emalex acquisition costs weigh on profits, while innovative drugs drive a revenue beat and an increased 2026 sales outlook.

Teva Pharmaceutical Industries (NYSE:TEVA) reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% from a year earlier in U.S. dollars, as lower sales from generic Revlimid were largely offset by growth in its innovative medicines portfolio. Chief Executive Officer Richard Franc

In the past week, Teva Pharmaceutical Industries reported Q2 2026 results showing largely flat sales of US$4,142 million year-on-year but shifting from net income of US$282 million to a net loss of US$576 million, driven in part by impairment charges and acquisition-related costs.

After years as a struggling generic-drug giant, Teva’s transformation under Richard Francis has pushed its valuation above $40 billion and raised the possibility of joining the S&P 500.